Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Susan H. Boklage"'
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Background Increased levels of cytokines, including interleukin-6 (IL-6), reflect inflammation and have been shown to be predictive of therapeutic responses, fatigue, pain, and depression in patients with rheumatoid arthritis (RA), but limit
Externí odkaz:
https://doaj.org/article/b860e9616b7c45618cb4e77fed50f962
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 3, Pp 517-535 (2020)
Abstract Introduction Tumor necrosis factor inhibitors (TNFi) are commonly used as first-line therapy (biologic disease-modifying antirheumatic drug [bDMARD] and targeted synthetic DMARD [tsDMARD]: defined as targeted therapy) for patients with moder
Externí odkaz:
https://doaj.org/article/72f4125fd6204cb8afbafb5934b0553d
Autor:
Cem Gabay, Gerd R. Burmester, Vibeke Strand, Jérôme Msihid, Moshe Zilberstein, Toshio Kimura, Hubert van Hoogstraten, Susan H. Boklage, Jonathan Sadeh, Neil M. H. Graham, Anita Boyapati
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a key role in the pathogenesis of rheumatoid arthritis. Sarilumab is a human monoclonal antibody that binds membrane-bound and soluble IL-6 receptor-α to inhibit IL-6 sign
Externí odkaz:
https://doaj.org/article/9f7d47705237485b86eba702a5fcce61
Autor:
Marjolein S. de Bruin-Weller, Mette Deleuran, Eric L. Simpson, Laurent Eckert, Susan H. Boklage, Randy Prescilla, Ashish Bansal, Paola Mina-Osorio, Zhen Chen
Publikováno v:
Journal of the American Academy of Dermatology. 83:AB29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3da2f57c2b85b78106838da9181f2cf0
https://doi.org/10.1016/j.jaad.2020.06.204
https://doi.org/10.1016/j.jaad.2020.06.204